SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Rumi Therapeutics Announces Licensing Agreement With Enthorin Therapeutics

The agreement concerns RTX-7340, an IND-ready PDE2 inhibitor for Fragile X syndrome.

Related stories